Drug Trial Radar · NCT06226350
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
Last checked: Nov 19, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Mar 4, 2021
Primary completion
Dec 5, 2023
Study completion Jan 3, 2024
Sponsor
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was an open, single-arm, enriched, multicenter Phase II study.
Conditions
- Cervical Cancer
Interventions
Recombinant Humanized Anti-PD-1 Monoclonal Antibody InjectionDrug
F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective tumor response rate (ORR) assessed by RECIST1.1Time frame: approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong New Time Pharmaceutical Co., LTD
Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.